Company research
Nascent Biotech Inc.
CIK 1622057Updated Sep 24, 2026
SecurityNBIO · OTC · equity
NBIO price & chart
Loading TradingView…
OTC:NBIO on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
No filing activity has been returned.
Financials
FY 2024 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 552,120Source | 255,002Source | 105,414Source | 751,435Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | 750,000Source |
| Assets, CurrentUSD | 552,120Source | 255,002Source | 105,414Source | 751,435Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 82,816Source | 11,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 808,794Source | 1,551,139Source | 776,890Source | 1,223,940Source |
| Commitments and ContingenciesUSD | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 170,594Source | 131,764Source | 111,313Source | 104,834Source |
| Additional Paid in CapitalUSD | 23,833,189Source | 20,194,874Source | 18,039,017Source | 17,774,023Source |
| Retained Earnings (Accumulated Deficit)USD | -24,260,457Source | -21,622,775Source | -18,821,806Source | -18,351,416Source |
| Stockholders' Equity Attributable to ParentUSD | -256,674Source | -1,296,137Source | -671,476Source | -472,505Source |
| Liabilities and EquityUSD | 552,120Source | 255,002Source | 105,414Source | 751,435Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 808,794Source | 1,551,139Source | 776,890Source | 1,223,940Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -2,087,682Source | 2,800,969Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 60,850Source | 60,000Source | 5,250Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | 0Source | 750,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,186,066Source | -1,787,228Source | 413,479Source | -986,784Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,386,000Source | 1,865,000Source | -320,500Source | 985,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 372,120Source | 172,186Source | 94,414Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 11,135Source | 30,027Source | — |
| Income Taxes Paid, NetUSD | — | — | 0Source | — |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 377,909Source | 1,343,277Source | — | — |
| DepreciationUSD | — | 0Source | 0Source | — |
| Financing Interest ExpenseUSD | 0Source | — | — | — |
| Gain (Loss) on Sale of DerivativesUSD | — | 1,054,786Source | 468,823Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | 50,000Source | 28,000Source | 0Source | 151,308Source |
| General and Administrative ExpenseUSD | 403,589Source | 405,295Source | 379,424Source | 359,259Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -2,087,682Source | -2,800,969Source | -470,390Source | -958,767Source |
| Operating ExpensesUSD | 2,229,879Source | 2,155,757Source | 1,457,052Source | — |
| Other Nonoperating Income (Expense)USD | 142,197Source | -645,212Source | -13,338Source | 441,601Source |
| Payments of Financing CostsUSD | — | — | — | 19,411Source |
| Proceeds from Issuance of Common StockUSD | 1,561,000Source | — | — | 0Source |
| Stock or Unit Option Plan ExpenseUSD | 48,000Source | 72,000Source | — | — |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | — | 0Source | 1,000,000Source | 750,000Source |
| Operating Income (Loss)USD | -2,229,879Source | -2,155,757Source | -457,052Source | -1,400,368Source |
| Other Nonoperating Income (Expense)USD | 142,197Source | -645,212Source | -13,338Source | 441,601Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -2,087,682Source | -2,800,969Source | -470,390Source | -958,767Source |
| Additional Financial Items | ||||
| Financing Interest ExpenseUSD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 403,589Source | 405,295Source | 379,424Source | 359,259Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -2,087,682Source | -2,800,969Source | -470,390Source | -958,767Source |
| Interest ExpenseUSD | 385,236Source | 1,566,919Source | 48,044Source | 269,382Source |
| Interest Income, OperatingUSD | — | 274Source | 12Source | 5Source |
| Interest Income, OtherUSD | 5,265Source | — | — | — |
| Operating ExpensesUSD | 2,229,879Source | 2,155,757Source | 1,457,052Source | — |
| Other ExpensesUSD | — | — | 0Source | 369Source |
| Research and Development ExpenseUSD | 110,975Source | 270,529Source | 197,406Source | 321,938Source |